216 related articles for article (PubMed ID: 38332687)
21. Metabolic Tumor Burden Assessed by Dual Time Point [
Garcia-Vicente AM; Pérez-Beteta J; Pérez-García VM; Molina D; Jiménez-Londoño GA; Soriano-Castrejón A; Martínez-González A
Mol Imaging Biol; 2017 Aug; 19(4):636-644. PubMed ID: 27981471
[TBL] [Abstract][Full Text] [Related]
22. Subtype-Guided
Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G
Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448
[TBL] [Abstract][Full Text] [Related]
23. Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy.
Koolen BB; Vrancken Peeters MJ; Wesseling J; Lips EH; Vogel WV; Aukema TS; van Werkhoven E; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1830-8. PubMed ID: 22895862
[TBL] [Abstract][Full Text] [Related]
24. Tumour 18 F-FDG Uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes.
Kim JY; Lee SH; Kim S; Kang T; Bae YT
Eur Radiol; 2015 Apr; 25(4):1172-81. PubMed ID: 25298170
[TBL] [Abstract][Full Text] [Related]
25. The correlation of
Qu YH; Long N; Ran C; Sun J
Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540
[TBL] [Abstract][Full Text] [Related]
26. Dynamic 2-Deoxy-2-[
Kristian A; Holtedahl JE; Torheim T; Futsaether C; Hernes E; Engebraaten O; Mælandsmo GM; Malinen E
Mol Imaging Biol; 2017 Apr; 19(2):271-279. PubMed ID: 27541026
[TBL] [Abstract][Full Text] [Related]
27. Implications of standardized uptake value measurements of the primary lesions in proven cases of breast carcinoma with different degree of disease burden at diagnosis: does 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography predict tumor biology?
Basu S; Mavi A; Cermik T; Houseni M; Alavi A
Mol Imaging Biol; 2008; 10(1):62-6. PubMed ID: 18000713
[TBL] [Abstract][Full Text] [Related]
28. Comparisons of [18F]-1-deoxy-1-fluoro-scyllo-inositol with [18F]-FDG for PET imaging of inflammation, breast and brain cancer xenografts in athymic mice.
McLarty K; Moran MD; Scollard DA; Chan C; Sabha N; Mukherjee J; Guha A; McLaurin J; Nitz M; Houle S; Wilson AA; Reilly RM; Vasdev N
Nucl Med Biol; 2011 Oct; 38(7):953-9. PubMed ID: 21982567
[TBL] [Abstract][Full Text] [Related]
29. Intra-tumour 18F-FDG uptake heterogeneity decreases the reliability on target volume definition with positron emission tomography/computed tomography imaging.
Dong X; Wu P; Sun X; Li W; Wan H; Yu J; Xing L
J Med Imaging Radiat Oncol; 2015 Jun; 59(3):338-45. PubMed ID: 25708154
[TBL] [Abstract][Full Text] [Related]
30. Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition.
Boers J; Venema CM; de Vries EFJ; Glaudemans AWJM; Kwee TC; Schuuring E; Martens JWM; Elias SG; Hospers GAP; Schröder CP
Eur J Cancer; 2020 Feb; 126():11-20. PubMed ID: 31891878
[TBL] [Abstract][Full Text] [Related]
31. Predictive Value of
Song BI; Kim HW; Won KS
Ann Surg Oncol; 2017 Aug; 24(8):2174-2181. PubMed ID: 28432480
[TBL] [Abstract][Full Text] [Related]
32. 18F-Deoxyglucose (18F-FDG) Positron Emission Tomography/Computed Tomography (PET/CT) Monitoring of Dynamic Growth Characteristics of Walker-256 Tumor Models in 3 Different Locations in Rats.
Li P; Liu Q; Wang X; Huang G; Song S
Med Sci Monit; 2019 Jan; 25():558-564. PubMed ID: 30659557
[TBL] [Abstract][Full Text] [Related]
33. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis.
Avril N; Menzel M; Dose J; Schelling M; Weber W; Jänicke F; Nathrath W; Schwaiger M
J Nucl Med; 2001 Jan; 42(1):9-16. PubMed ID: 11197987
[TBL] [Abstract][Full Text] [Related]
34. Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1-11C]tyrosine PET.
Kole AC; Nieweg OE; Pruim J; Paans AM; Plukker JT; Hoekstra HJ; Schraffordt Koops H; Vaalburg W
J Nucl Med; 1997 May; 38(5):692-6. PubMed ID: 9170429
[TBL] [Abstract][Full Text] [Related]
35. Evaluating heterogeneity of primary tumor (18)F-FDG uptake in breast cancer with a dedicated breast PET (MAMMI): a feasibility study based on correlation with PET/CT.
Koolen BB; Vidal-Sicart S; Benlloch Baviera JM; Valdés Olmos RA
Nucl Med Commun; 2014 May; 35(5):446-52. PubMed ID: 24686195
[TBL] [Abstract][Full Text] [Related]
36. Early Response Monitoring Following Radiation Therapy by Using [
Chung YH; Tsai CK; Wang CC; Chen HM; Lu KY; Chiu H; Lin YC; Yen TC; Lin G
Molecules; 2017 Nov; 22(11):. PubMed ID: 29125557
[TBL] [Abstract][Full Text] [Related]
37. Radiogenomic analysis of primary breast cancer reveals [18F]-fluorodeoxglucose dynamic flux-constants are positively associated with immune pathways and outperform static uptake measures in associating with glucose metabolism.
Ralli GP; Carter RD; McGowan DR; Cheng WC; Liu D; Teoh EJ; Patel N; Gleeson F; Harris AL; Lord SR; Buffa FM; Fenwick JD
Breast Cancer Res; 2022 May; 24(1):34. PubMed ID: 35581637
[TBL] [Abstract][Full Text] [Related]
38. Background Intestinal 18F-FDG Uptake Is Related to Serum Lipid Profile and Obesity in Breast Cancer Patients.
Yoon HJ; Kim HN; Yun Y; Kim Y; Ha AN; Kim HL; Kim BS
PLoS One; 2015; 10(11):e0141473. PubMed ID: 26523374
[TBL] [Abstract][Full Text] [Related]
39. Biological characterisation of breast cancer by means of PET.
Buck AK; Schirrmeister H; Mattfeldt T; Reske SN
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S80-7. PubMed ID: 15127240
[TBL] [Abstract][Full Text] [Related]
40. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
